Health News Releases

  • Today December 7
July 12, 15:20
ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders’ Voices Expressed at the AGM
ILJIN SNT Co., Ltd. (“ILJIN”), one of the largest shareholders of Aurinia Pharmaceuticals (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued an open letter to fellow shareholders. The full text
July 12, 11:30
Parse Biosciences Launches Certified Service Provider Program
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54093141&newsitemid=20240711445815&lan=en-US&anchor=Parse+Biosciences&index=1&md
July 11, 15:50
Viromed Medical AG Seeks Special Approval for Cold Plasma Device for the Prevention of Ventilator-Associated Pneumonia (VAP)
Viromed Medical AG (ISIN: DE000A3MQR65; “Viromed”) is launching a second pioneering study on the use of cold plasma for the prevention of ventilator-associated pneumonia (VAP). The study, under the sc
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
July 11, 11:41
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda Therapeutics, Inc. AMPYRA® (dalfamprid
July 10, 15:56
Brandnew Lab launches three ‘Nuvoen’ ampoule series for clinics
Brandnew Lab announced that it has launched three ampoule products - Boost, Lipo, and PLLA - under its clinic solution brand ‘Nuvoen’, which has the slogan ‘bring new vitality to the skin’, on July 10
July 10, 15:25
MMI Builds Global Momentum with Multiple Distribution Agreements and Regulatory Approvals
MMI (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.mmimicro.com%2F&esheet=54090621&newsitemid=20240709821670&lan=en-US&anchor=MMI&index=1&md5=df42141cdf355f8be68a32aeb0578189)
DRX-Evolution Plus (Photo: Business Wire)
July 04, 14:10
Enhancing Technologist Experience and Patient Workflow, Carestream Reveals New Enhancements to CARESTREAM DRX-Evolution Plus System and ImageView Software
Carestream Health announced today the addition of new enhancements to its ImageView Software and DRX-Evolution Plus System, marking the latest improvements to its line of innovative, industry-leading
July 04, 10:50
Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323
We are excited to share our latest development status. We are pleased to announce that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/da
July 01, 16:35
TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease
TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer’s disease (AD), has announced the submission of a UK Marketing Authorisation Application (MAA) for hydromethylthionine mes
Left to right: Mitchell Rubin, Medisca CFO | Assemblyman Billy Jones | Stephane Nizri, Medisca Head
June 28, 14:10
Medisca Opens New Pharmaceutical Repackaging Facility to Meet Global Demands in Personalized Medicine
Medisca, a global leader in personalized pharmaceutical solutions, held a grand opening event on June 20, 2024, for their new repackaging and distribution facility in Plattsburgh, New York. The event
QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri
June 28, 11:30
QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development
QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capab
June 27, 14:20
Takeda Announces New Assignments of Directors
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary M
ENCell presented promising results from their First-in-Human Phase 1 clinical trial of the novel me
June 27, 13:58
ENCell Presents the Phase 1 Clinical Trial Results of EN001 for Charcot-Marie-Tooth Disease at the PNS conference
ENCell Co., Ltd., a biotech in South Korea specializing in Cell and Gene therapy (CGT), presented promising results from their First-in-Human Phase 1 clinical trial of the novel mesenchymal stem cell
Danilo Neri - Partner & Vice President Executive at PQE Group (Photo: PQE Group)
June 27, 13:20
PQE Group Launches AI and Data Analytics Division: Innovation in the Service of Life Science
PQE Group, a leading consultancy in the Life Science sector, announces the consolidation of its new Regulated Artificial Intelligence & Data Analytics division operating since the initiation of AI bas
June 26, 14:45
Kenvue Releases Inaugural Healthy Lives Mission Report
Kenvue Inc. (NYSE: KVUE) (“Kenvue” or the “Company”), the world’s largest pure-play consumer health company by revenue, today released its first-ever Healthy Lives Mission Report and shared how the Co
June 26, 12:00
RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors
RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, F
June 25, 09:43
Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unres
June 25, 09:26
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54085563&newsitemid=20240624910432&lan=en-US&anchor=TSE%3A4
June 23, 16:00
Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials
The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri (https://www.esri.com/en-us/about/ab
June 23, 13:54
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, to
June 23, 12:47
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment
QPS Holdings, LLC corporate headquarters in Delaware Technology Park in Newark, Delaware. This locat
June 21, 13:40
QPS Announces New Global Clinical Research Operations Leadership
QPS, a leading global contract research organization (CRO), is pleased to announce new clinical research operations leadership. This new clinical leadership will further align the existing global medi
June 21, 11:25
C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products
C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to ac
June 20, 14:15
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54067141&newsitemid=20240618911375&lan=en-US&anchor=%28TSE%3A4502%2FNY
June 19, 16:55
Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence
Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation
June 19, 15:15
Kirin Holdings Commences Tender Offer To Make FANCL A Wholly-Owned Subsidiary
Kirin Holdings Company, Limited (Kirin Holdings) (TOKYO: 2503) has decided to acquire additional shares of common stock of FANCL Corporation (FANCL) (TOKYO: 4921) through a tender offer and share warr
June 19, 10:00
Medidata Launches Clinical Data Studio, Leveraging AI to Modernize the Data Experience in Clinical Trials
Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2F&esheet=54053800&newsitemid=20240618137167&lan=en-US&anchor=Medidata&index=1&md5=9b4ee92db6a3a74cfb7
Carestream DRYVIEW 5700C (Photo: Business Wire)
June 18, 15:35
Carestream Secures Crucial Business Partner Agreement in Peru
Carestream Health recently secured an agreement with Distribuidora Diagnostica Medica SAC (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdmdperu.com%2F&esheet=54063578&newsitemid=2
June 18, 09:05
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54062720&newsitemid=20240617592767&lan=en-US&anchor=TSE%3A4
June 16, 10:00
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54061414&newsitemid=20240614852542&lan=en-US&anchor=TSE%3A4502%2FNYSE%
RegenLab France receives prestigious EU-EIB Innovation Champion Award. Antoine Turzi, CEO and Founde
June 13, 14:15
RegenLab France Receives Prestigious EU-EIB Innovation Champion Award
RegenLab (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftrack.regenlab.com%2Fe%2F915601%2Ffr-accueil-%2Fnh859%2F499945919%2Fh%2FMJGMMXyPSguyCEA8gEgmux2pgRtnhNF3rpVyUTCRZ9Y&esheet=5
Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus
June 12, 10:25
Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results
AOP Orphan Pharmaceuticals GmbH (AOP Health) continues a successful clinical research program in hematology/oncology with two abstracts accepted for presentation at the European Hematology Association
New Erbe production and development building in Rangendingen, Germany (Photo: Business Wire)
June 07, 11:55
Erbe Elektromedizin inaugurates new competence center for medical instruments in Rangendingen, Germany, and expands its capacities for customers all over the world
Erbe Elektromedizin has inaugurated a new production and development building in Rangendingen, Germany, after three years of construction. At 90 million euros, the new 25,000 m² building is the larges
Image rendering of OmniAb’s OmnidAb™, a stabilized fully human heavy chain only single domain antibo
June 05, 11:20
OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology
OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journ
Masimo W1®, Radius VSM™, Root®, Patient SafetyNet™, and UniView® (Photo: Business Wire)
June 04, 10:05
Germans Trias i Pujol Hospital in Spain Launches Telehealth and Remote Patient Management Program Using Masimo W1® Medical Watches and Radius VSM™ Wearable Continuous Vital Signs Monitors
Masimo (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54024712&newsitemid=20240602519106&lan=en-US&anchor=Masimo&index=1&md5=2fa389b04192756b6c102775397cd8f2)
June 04, 09:32
Merck’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment
Merck, a leading science and technology company, today shared updates on the company’s oncology pipeline and focused approach to the research and development of potential new medicines designed to imp
June 04, 08:57
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
Takeda (TSE: 4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54024400&newsitemid=20240531655762&lan=en-US&anchor=TSE%3A
June 02, 15:30
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with
Human-Residential Bifidobacteria (HRB) strains such as Bifidobacterium longum BB536, B. breve M-16V,
June 02, 13:35
Morinaga Milk’s New Research Breakthrough Backed the Superiority of its Human-Residential Bifidobacteria (HRB) Strains in Metabolizing Toxin Precursor in the Gut
Morinaga Milk Industry Co., Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.morinagamilk.co.jp%2Fenglish%2F&esheet=54016718&newsitemid=20240530532346&lan=en-US&anchor=Morina
June 02, 13:33
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54024414&newsitemid=20240531914145&lan=en-US&anchor=TSE%3A4
His Excellency Dr. Sultan Ahmed Al Jaber, Minister of Industry and Advanced Technology (Photo: AETOS
June 02, 13:20
UAE Commits Additional $6.26b in Industrial Offtakes
Government enterprises and private companies in the UAE committed an additional $6.26 billion to local manufacturing during the Make it in the Emirates (MIITE) Forum, which concluded on Tuesday. Organ
May 31, 15:05
Parse Biosciences Launches Trailmaker Data Analysis Platform to Simplify Single Cell Sequencing
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.parsebiosciences.com&esheet=54020000&newsitemid=20240530324847&lan=en-US&anchor=Parse+Biosciences&index=1&md5=af
May 31, 15:00
Rhea Launches with Senior Advisory Panel, Growth Acquisitions and Strategic Partnerships to Advance Fertility Journeys for the Modern Family
Rhea (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.rhea-fertility.com%2F&esheet=54023155&newsitemid=20240530629751&lan=en-US&anchor=Rhea&index=1&md5=6bdc47f71fce37fda87be39181
May 30, 16:45
JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)
JJP Biologics, a private biopharmaceutical company developing innovative antibody-based therapies, announces a positive decision, issued by the European Medicines Agency, on the Clinical Trial Applica
May 30, 16:05
Asymchem Welcomes Franck Mevellec as Senior Director, Business Development
Asymchem (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fasymchem.com%2F&esheet=54019791&newsitemid=20240529046363&lan=en-US&anchor=Asymchem&index=1&md5=1c205c848b9ccf2653c34e49187b
May 30, 14:55
Lenovo Powers AI Avatars to Explore the Role of Technology in Mental Health
Today, Lenovo™ released the newest iteration of its Work For Humankind (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Flenovowfh.com%2F&esheet=54018442&newsitemid=20240528448000&lan
From left to right: Kwang-Hyung Lee, President of KAIST, Matthias Heinzel, Member of the Executive B
May 30, 10:15
Merck Signs MoU with KAIST to Advance Scientific Collaboration
Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST). The academia-industry c
May 30, 09:30
TVM Capital Healthcare Announces the Closing of its Saudi Arabia-Focused TVM Healthcare Afiyah Fund
TVM Capital Healthcare, an international healthcare expansion and growth capital investor, today announced the closing of the TVM Healthcare Afiyah Fund LP at approximately USD 250 million, its second
May 29, 11:55
Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)
The international pharmaceutical BCorp company Ferrer continues to strengthen its focus on pulmonary vascular and interstitial lung diseases by announcing the expansion of its current distribution agr
May 28, 14:58
Oncocross and JW Pharmaceutical Team Up on AI-powered Drugs for Cancer and Regeneration
Oncocross, an AI biotech company specializing in drug discovery and development, announced that it has signed a joint research agreement with JW Pharmaceutical to develop new drugs based on the AI pl
25 per page50 per page75 per page100 per page